Prevalence of Bronchiectasis in COPD Patients

Bronchiectasis Clinical Trial

Official title:

Prevalence of and Prognostic Impact of Bronchiectasis in COPD Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04101448
• Other study ID #: AssiutU7
• Status: Recruiting
• Start date: September 30, 2019
• Est. completion date: September 30, 2020

Study information

• Verified date: September 2019
• Source: Assiut University
• Contact: Aliae Mohamed-Hussein
• Phone: 01222302352
• Email: aliaehussein[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Description:

The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 30, 2020
• Est. primary completion date: September 1, 2020
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• COPD patients based on GOLD 2019 criteria, stable or in exacerbation

Exclusion Criteria:

• acute pneumonia within 2 months

• malignancy

• congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome).

• Pregnancy

Related Conditions & MeSH terms

• Bronchiectasis
• Chronic Obstruct Airways Disease
• Prognosis
• Pulmonary Disease, Chronic Obstructive

Intervention

Other:
• prevalence
percentage of bronchectasis in COPD and its effect as prognostic measure

Locations

Country	Name	City	State
Egypt	AssiutU	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of Bronchiectasis in COPD	percentage of bronchiectasis diagnosed by CT chest in COPD patients	1 year
Secondary	impact of bronchiectasis on COPD exacerbations	number of exacerbations treated in or out of hospitals	1 year
Secondary	impact of bronchiectasis on COPD hospitalization	number of hospital admissions with acute exacerbations	1 year
Secondary	impact of bronchiectasis on COPD intensive care admission	number of admissions in respiratory ICU and need for mechanical or non invasive ventilation	1 year